FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304014062> ?p ?o ?g. }

• W4304014062 endingPage "e2235060" @default.
• W4304014062 startingPage "e2235060" @default.
• W4304014062 abstract "Importance In osteoarthritis (OA) clinical trials, a placebo is often used as control. Therefore, a thorough understanding of the placebo response is important for guiding drug development in OA. Objective To develop an oral placebo response model for OA. Data Sources PubMed, EMBASE, and Cochrane Library databases were searched systematically from January 1, 1991, to July 2, 2022. Study Selection Randomized double-blind placebo-controlled trials of patients with primary OA were included. The interventions and placebo were administered orally. A total of 3032 trials were identified; of these, 130 (4.3%) met the inclusion criteria. Data Extraction and Synthesis Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, dosage form of the placebo, sample size, proportion of patients who previously used nonsteroidal anti-inflammatory drugs, publication year, intervention categories, Kellgren-Lawrence grades, proportion of White patients, duration of pain, funding source, and risk of bias were extracted. A model-based meta-analysis was used to evaluate the time course of the placebo response in OA treatment and estimate the influencing factors. For subgroup analyses, a meta-analysis with a random-effects model was used to summarize the typical values of the model parameters and their SEs. Main Outcomes and Measures The primary end point was the time course of the oral placebo response on the WOMAC pain, stiffness, and function subscale scores. Results The 130 trials selected for analysis included 12 673 participants (mean age, 59.9 years; 68.9% women). The baseline scores of WOMAC pain, stiffness, and function subscales were found to be significantly associated with the placebo response. The placebo response reached 90% of its maximum response between 5 and 7 weeks. The placebo responses on the WOMAC subscales were also associated with the sample size, proportion of patients who had previously used nonsteroidal anti-inflammatory drugs, intervention drugs, and publication year. Conclusions and Relevance In this study, an oral placebo response model of OA was developed that may quantitatively describe the placebo response at different baseline levels of symptoms. The findings may provide valuable references for future clinical trial design and decision-making." @default.
• W4304014062 created "2022-10-10" @default.
• W4304014062 creator A5007507673 @default.
• W4304014062 creator A5023963796 @default.
• W4304014062 creator A5028396118 @default.
• W4304014062 creator A5029946717 @default.
• W4304014062 creator A5035746108 @default.
• W4304014062 creator A5052385150 @default.
• W4304014062 creator A5063059435 @default.
• W4304014062 creator A5067048872 @default.
• W4304014062 creator A5074247805 @default.
• W4304014062 creator A5074419127 @default.
• W4304014062 creator A5077556517 @default.
• W4304014062 creator A5082958570 @default.
• W4304014062 date "2022-10-10" @default.
• W4304014062 modified "2023-10-17" @default.
• W4304014062 title "Placebo Response to Oral Administration in Osteoarthritis Clinical Trials and Its Associated Factors" @default.
• W4304014062 cites W1963826852 @default.
• W4304014062 cites W1986040950 @default.
• W4304014062 cites W2023625718 @default.
• W4304014062 cites W2028439163 @default.
• W4304014062 cites W2031210704 @default.
• W4304014062 cites W2098923148 @default.
• W4304014062 cites W2135956897 @default.
• W4304014062 cites W2274722622 @default.
• W4304014062 cites W2588681363 @default.
• W4304014062 cites W2606439041 @default.
• W4304014062 cites W2746285343 @default.
• W4304014062 cites W2937912490 @default.
• W4304014062 cites W2950759421 @default.
• W4304014062 cites W2966378135 @default.
• W4304014062 cites W2990329742 @default.
• W4304014062 cites W2991537231 @default.
• W4304014062 cites W3000036091 @default.
• W4304014062 cites W3007420257 @default.
• W4304014062 cites W3011139488 @default.
• W4304014062 cites W3028960911 @default.
• W4304014062 cites W3119762460 @default.
• W4304014062 cites W3130653527 @default.
• W4304014062 cites W3214377991 @default.
• W4304014062 cites W4211067786 @default.
• W4304014062 cites W4238759536 @default.
• W4304014062 cites W4255442096 @default.
• W4304014062 doi "https://doi.org/10.1001/jamanetworkopen.2022.35060" @default.
• W4304014062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36215072" @default.
• W4304014062 hasPublicationYear "2022" @default.
• W4304014062 type Work @default.
• W4304014062 citedByCount "4" @default.
• W4304014062 countsByYear W43040140622022 @default.
• W4304014062 countsByYear W43040140622023 @default.
• W4304014062 crossrefType "journal-article" @default.
• W4304014062 hasAuthorship W4304014062A5007507673 @default.
• W4304014062 hasAuthorship W4304014062A5023963796 @default.
• W4304014062 hasAuthorship W4304014062A5028396118 @default.
• W4304014062 hasAuthorship W4304014062A5029946717 @default.
• W4304014062 hasAuthorship W4304014062A5035746108 @default.
• W4304014062 hasAuthorship W4304014062A5052385150 @default.
• W4304014062 hasAuthorship W4304014062A5063059435 @default.
• W4304014062 hasAuthorship W4304014062A5067048872 @default.
• W4304014062 hasAuthorship W4304014062A5074247805 @default.
• W4304014062 hasAuthorship W4304014062A5074419127 @default.
• W4304014062 hasAuthorship W4304014062A5077556517 @default.
• W4304014062 hasAuthorship W4304014062A5082958570 @default.
• W4304014062 hasBestOaLocation W43040140621 @default.
• W4304014062 hasConcept C126322002 @default.
• W4304014062 hasConcept C142724271 @default.
• W4304014062 hasConcept C168563851 @default.
• W4304014062 hasConcept C1862650 @default.
• W4304014062 hasConcept C204787440 @default.
• W4304014062 hasConcept C27081682 @default.
• W4304014062 hasConcept C2776164576 @default.
• W4304014062 hasConcept C2776478404 @default.
• W4304014062 hasConcept C2779286237 @default.
• W4304014062 hasConcept C535046627 @default.
• W4304014062 hasConcept C71924100 @default.
• W4304014062 hasConcept C95190672 @default.
• W4304014062 hasConceptScore W4304014062C126322002 @default.
• W4304014062 hasConceptScore W4304014062C142724271 @default.
• W4304014062 hasConceptScore W4304014062C168563851 @default.
• W4304014062 hasConceptScore W4304014062C1862650 @default.
• W4304014062 hasConceptScore W4304014062C204787440 @default.
• W4304014062 hasConceptScore W4304014062C27081682 @default.
• W4304014062 hasConceptScore W4304014062C2776164576 @default.
• W4304014062 hasConceptScore W4304014062C2776478404 @default.
• W4304014062 hasConceptScore W4304014062C2779286237 @default.
• W4304014062 hasConceptScore W4304014062C535046627 @default.
• W4304014062 hasConceptScore W4304014062C71924100 @default.
• W4304014062 hasConceptScore W4304014062C95190672 @default.
• W4304014062 hasIssue "10" @default.
• W4304014062 hasLocation W43040140621 @default.
• W4304014062 hasLocation W43040140622 @default.
• W4304014062 hasLocation W43040140623 @default.
• W4304014062 hasOpenAccess W4304014062 @default.
• W4304014062 hasPrimaryLocation W43040140621 @default.
• W4304014062 hasRelatedWork W2153862724 @default.
• W4304014062 hasRelatedWork W2287567982 @default.
• W4304014062 hasRelatedWork W2596704481 @default.
• W4304014062 hasRelatedWork W3096683796 @default.

• next